Charité–Universitätsmedizin Berlin

A single CD19 CAR-T infusion held three of six refractory rheumatoid arthritis patients drug-free

The Berlin phase 1 trial was built to measure cytokine release syndrome rather than remission, and its six-patient denominator carries no comparator, so the ten-patient second phase against an approved B-cell drug is the one that settles anything.